SavaDx is a blood-based biomarker/diagnostic candidate to detect Alzheimer’s disease.

SavaDx (formerly known as PTI-125Dx) is our blood-based diagnostic to detect Alzheimer’s disease.

The goal of SavaDx is to make the detection of Alzheimer’s disease as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.

We are developing SavaDx as a simple, accurate and quantitative blood-based diagnostic to detect and monitor Alzheimer's disease. If successful, we believe SavaDx has potential to make obsolete many of the current approaches for diagnosing Alzheimer’s disease.

In blinded studies, our investigational diagnostic, SavaDx, detected >10-fold differences between patients with Alzheimer’s and age-matched normal controls or young cognitively intact subjects (N=232).

This clinical-stage program is funded by research grants from the National Institutes of Health (NIH).